$1.04
arrow_drop_up0.48%Key Stats | |
---|---|
Open | $1.05 |
Prev. Close | $1.03 |
EPS | -1.77 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $57.23M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.00 | 1.10 |
52 Week Range | 1.00 | 6.80 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.77 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting